AI Article Synopsis
- Sweet syndrome is a skin condition characterized by neutrophilic inflammation, often occurring without a known cause, but can be related to medications or certain cancers.
- This case report details the first instance of Sweet syndrome appearing in a patient with lung adenocarcinoma after starting treatment with erlotinib.
- The findings suggest a potential link between the use of the EGFR tyrosine kinase inhibitor and the development of Sweet syndrome, marking a novel connection not previously documented in medical literature.
Article Abstract
Introduction: Sweet syndrome is a neutrophilic dermatosis and is often idiopathic, although its onset may be drug-induced or paraneoplastic. The purpose of this case report is to describe the very first occurrence of Sweet syndrome following erlotinib intake in a patient diagnosed with lung adenocarcinoma.
Patients And Methods: We observed Sweet syndrome, as assessed by clinical, laboratory and histological examination, in a middle-aged female patient presenting lung adenocarcinoma diagnosed three years prior to her cutaneous symptoms.
Discussion: Given the extremely long time between the diagnosis of lung cancer and the onset of Sweet syndrome, as well as the occurrence of skin lesions during administration of the medication and their subsidence after drug withdrawal, we suggest a possible link between this particular EGFR tyrosine kinase inhibitor and the patient's neutrophilic dermatological signs. To our knowledge this association has not previously been described in the medical literature.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.annder.2019.10.030 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!